Another two multicentre, randomized, sham-controlled phase 3 clinical trials conducted in France, Germany, Italy, the UK, and the USA, REVERSE (NCT02652780) and RESCUE (NCT02652767) also evaluated the efficacy of rAAV2-ND4 among LHON patients [78, 79]. Here, MT-ND4 is linked to Leber hereditary optic neuropathy.